| Previous Close | 5.01 |
| Open | 5.27 |
| Bid | 5.02 x 0 |
| Ask | 5.27 x 0 |
| Day's Range | 5.01 - 5.27 |
| 52 Week Range | 4.35 - 13.79 |
| Volume | 400 |
| Avg. Volume | 979 |
| Market Cap | 99.678M |
| Beta (3Y Monthly) | 0.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.57 |
| Earnings Date | Mar 28, 2018 - Apr 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RESEARCH TRIANGLE PARK, N.C., June 19, 2019 -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management.
Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK,.
Reported financial results for the fiscal year ended December 31, 2018. Cash and cash equivalents were ...
Initiated rolling New Drug Application to U.S. FDA for PEDMARKTMSecured $12. 5 million debt financing to support a potential commercial launch Strong financial position with.
The U.S. operating subsidiary of Fennec Pharmaceuticals Inc. entered into a Loan and Security Agreement with Bridge Bank, securing a $12.5 million debt facility with a maturity date of October 1, 2023, which will be funded upon New Drug Application (NDA) approval of PEDMARKTM in the U.S. The Company intends to use the proceeds from the loan to provide working capital for commercialization activities for PEDMARKTM upon NDA approval. “We welcome the commitment of Bridge Bank to Fennec as this debt facility provides us with the option to access minimally dilutive capital at an attractive cost upon NDA approval.
NEW YORK, NY / ACCESSWIRE / January 10, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...
PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM.
Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTMTargeting US approval of PEDMARKTM in the second half of 2019Strong financial position with $24.5.
NEW YORK, NY / ACCESSWIRE / October 30, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
NEW YORK, NY / ACCESSWIRE / September 27, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...